Research Advances

A recent study reveals that the microRNA miR-362-3p acts as a powerful tumor suppressor in gastric cancer. Researchers found that high levels of miR-362-3p slow cancer cell growth, reduce migration, and prevent the epithelial-mesenchymal transition, which allows tumors to become more invasive. The study showed that miR-362-3p directly targets DEP-1, a protein that promotes tumor […]

A recent study uncovers a new mechanism by which colorectal cancer (CRC) evades the immune system and resists PD-L1 blockade. Researchers found that the protein G3BP2 undergoes acetylation at lysine 76 (K76), a modification added by the acetyltransferase p300 and removed by the deacetylase HDAC6. This acetylation stabilizes PD-L1 mRNA through interaction with PABPC1, increasing PD-L1

A new study reveals why PARP inhibitors—targeted drugs used in ovarian cancer—work well for some patients but fail in others. Using advanced imaging of live human tumor samples, researchers found that the key difference lies in how these drugs spread and behave inside individual cancer cells. The study shows that some PARP inhibitors, such as

New research highlights DNA methylation, a reversible epigenetic change, as a key factor in pancreatic ductal adenocarcinoma (PDAC) development, diagnosis, and treatment. In PDAC, tumor suppressor genes like p16 and E-cadherin are often “switched off” through hypermethylation, while oncogenes such as S100P and Maspin become abnormally active due to global hypomethylation, driving tumor growth and

Researchers have discovered why Small Cell Lung Cancer is so aggressive and likely to relapse. They found that these cancer cells are missing a key protein called caspase-8, which normally helps cells die in a controlled way. Without it, the cells die through a different process called necroptosis, which triggers inflammation. This inflammation creates a

Real-world data show that axatilimab (Niktimvo) is highly effective for patients with severe, treatment-resistant chronic graft-versus-host disease (cGVHD). The analysis included 104 patients, most of whom had severe disease affecting multiple organs and had tried a median of four prior therapies, including ruxolitinib (Jakafi) and belumosudil (Rezurock). Pediatric patients under 17 made up 10.6% of

Researchers used single-nucleus RNA sequencing to study pancreatic ductal adenocarcinoma (PDAC) cachexia, revealing how tumors systematically break down skeletal muscle. Using a KPC mouse model, they discovered a unique “cachectic cluster” of muscle nuclei that activates protein-degrading genes while suppressing structural genes. Not all muscle fibers were equally affected—fast-glycolytic Type IIb fibers suffered the most,

Researchers have developed a new blood test that could greatly improve early detection of pancreatic ductal adenocarcinoma, one of the most aggressive cancers. Traditional markers such as CA19-9 and THBS2 often lack accuracy when used alone, limiting their usefulness in screening. The new approach combines four proteins—CA19-9, THBS2, and two newly identified markers, ANPEP and

Researchers have developed a new cancer treatment approach using engineered bacteria, offering a different way to deliver chemotherapy more precisely. In the study, scientists modified a probiotic strain of Escherichia coli Nissle 1917 so it could produce Romidepsin, an FDA-approved cancer drug. When tested in mice, the engineered bacteria naturally moved toward breast cancer tumors and

A new study maps the peripheral immune system of treatment-naive pancreatic ductal adenocarcinoma (PDAC) patients using high-dimensional spectral flow cytometry. By analyzing over 70 immune cell subsets, researchers identified changes in the immune system that distinguish PDAC patients from healthy individuals. This method measures 40+ surface proteins directly, offering detailed insights into functional immune states